View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi S. u. 2/A 1083
Open access

Thrombocytopenia alatt a vérlemezkék számbeli csökkenését értjük. Ez a vérzékenység leggyakoribb oka. Klinikailag petechiák, purpurák megjelenése, nyálkahártyavérzés jellemzi. Előfordulhat azonban akár életet fenyegető, emésztőrendszert vagy központi idegrendszert érintő vérzés is. A haemostaseologiai laboratóriumi vizsgálatok közül a megnyúlt vérzési idő utal thrombocytaeredetű vérzékenységre. Kialakulásában vagy a csontvelői csökkent megakaryopoesis, vagy a fokozott thrombocytapusztulás, illetve a kettő kombinációja játszik szerepet. Thrombocytopenia észlelésekor a teendő az ok tisztázása. Ebben a csontvelő és a perifériás vérkenet vizsgálata mellett a háttérben álló feltételezett alapbetegség célzott diagnosztikája lehet segítségünkre. A kezelés részint az alapbetegséget célozza, részint a hiányzó komponens – a thrombocyta – pótlását jelenti. Utóbbi a thrombocyták aktiválódása és felhasználódása által előidézett kórképek esetén azonban szigorúan tilos, mivel a kórfolyamat progresszióját idézheti elő. Orv. Hetil., 2014, 155(8), 291–303.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Rodeghiero, F., Stasi, R., Gernsheimer, T., et al.: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113(11), 2386–2393.

  • Stasi, R., Amadori, S., Osborn, J., et al.: Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLos Med., 2006, 3(3), e24.

  • Mant, M. J., Doery, J. C., Gauldie, J., et al.: Pseudothrombocytopenia due to platelet aggregation and degranulation in blood collected in EDTA. Scand. J. Haematol., 1975, 15(3), 161–170.

  • Veneri, D., Franchini, M., Randon, F., et al.: Thrombocytopenias: a clinical point of view. Blood Transfus., 2009, 7(2), 75–85.

  • Gernsheimer, T.: Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist, 2009, 14(1), 12–21.

  • McMillan, R., Wang, L., Tomer, A., et al.: Suppression of in vitro megakaryocyte production by antiplatelet auto-antibodies from adult patients with chronic ITP. Blood, 2004, 103(4), 1364–1369.

  • Littman, D. R., Rudensky, A. Y.: Th17 and regulatory T cells in mediating and restraining inflammation. Cell, 2010, 140(6), 845–858.

  • Semple, J. W., Provan, D., Garvey, M. B., et al.: Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr. Opin. Hematol., 2010, 17(6), 590–595.

  • Thota, S., Kistangari, G., Daw, H., et al.: Immune thrombocytopenia in adults: an update. Cleve. Clin. J. Med., 2012, 79(9), 641–650.

  • Kojouri, K., Vesely, S. K., Terrell, D. R., et al : Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 2004, 104(9), 2623–2634.

  • Neunert, C., Lim, W., Crowther, M., et al.: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 2011, 117(16), 4190–4207.

  • Keating, G. M.: Romiplostim: a review of its use in immune thrombocytopenia. Drugs, 2012, 72(3), 415–435.

  • Catalá-López, F., Corrales, I., Martín-Serrano, G.: Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med. Clin. (Barc.), 2012, 139(10), 421–429.

  • Heddle, N. M., Soutar, R. L., O’Hoski, P. L., et al.: A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br. J. Haematol., 1995, 91(4), 1000–1005.

  • Shulman, N. R., Aster, R. H., Pearson, H. A., et al.: Immunoreactions involving platelets. VI. Reactions of maternal isoantibodies responsible for neonatal purpura. Differentiation of a second platelet antigen system. J. Clin. Invest., 1962, 41(5), 1059–1069.

  • Davoren, A., Curtis, B. R., Aster, R. H., et al.: Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion, 2004, 44(8), 1220–1225.

  • Bussel, J. B., Sola-Visner, M.: Current approaches to the evaluation and management of the fetus and neonate with immune thrombocytopenia. Semin. Perinat., 2009, 33(1), 35–42.

  • Warkentin, T. E., Eikelboom, J. W.: Who is (still) getting HIT? Chest, 2007, 131(6), 1620–1622.

  • Martel, N., Lee, J., Wells, P. S.: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood, 2005, 106(8), 2710–2715.

  • Sakr, Y.: Heparin-induced thrombocytopenia in the ICU: an overview. Crit. Care, 2011, 15(2), 211.

  • Shantsila, E., Lip, G. Y., Chong, B. H.: Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest, 2009, 135(6), 1651–1664.

  • Warkentin, T. E., Cook, R. J., Marder, V. J., et al.: Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood, 2005, 106(12), 3791–3796.

  • Selleng, K., Warkentin, T. E., Greinacher, A.: Heparin-induced thrombocytopenia in intensive care patients. Crit. Care Med., 2007, 35(4), 1165–1176.

  • Warkentin, T. E.: HIT: treatment easier, prevention harder. Blood, 2012, 119(5), 1099–1100.

  • Linkins, L. A., Warkentin, T. E.: The approach to heparin-induced thrombocytopenia. Semin. Respir. Crit. Care Med., 2008, 29(1), 66–74.

  • Greinacher, A., Farner, B., Kroll, H., et al.: Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb. Haemost., 2005, 94(1), 132–135.

  • Warkentin, T. E.: Heparin-induced thrombocytopenia. Dis. Mon., 2005, 51(2), 141–149.

  • Ruf, K. M., Bensadoun, E. S., Davis, G. A., et al.: A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopenia. Thromb. Haemost., 2011, 105(3), 553–559.

  • Lo, G. K., Juhl, D., Warkentin, T. E., et al.: Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J. Thromb. Haemost., 2006, 4(4), 759–765.

  • Wirth, S. M., Macaulay, T. E., Armitstead, J. A., et al.: Evaluation of a clinical scoring scale to direct early appropriate therapy in heparin-induced thrombocytopenia. J. Oncol. Pharm. Pract., 2010, 16(3), 161–166.

  • Warkentin, T. E., Hayward, C. P., Smith, C. A., et al.: Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J. Lab. Clin. Med., 1992, 120(3), 371–379.

  • Eichler, P., Budde, U., Haas, S., et al.: First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb. Haemost., 1999, 81(4), 625–629.

  • Greinacher, A., Eichler, P., Lubenow, N., et al.: Heparin-induced thrombocytopenia with thromboembolic complications: a meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood, 2000, 96(3), 846–851.

  • Hursting, M. J., Verme-Gobboney, C. N.: Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J. Cardiovasc. Pharmacol., 2008, 52(6), 561–566.

  • Warkentin, T. E.: HIT paradigms and paradoxes. J. Thromb. Haemost., 2011, 9(Suppl. 1), 105–117.

  • Krauel, K., Hackbarth, C., Fürll, B., et al.: Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood, 2012, 119(5), 1248–1255.

  • Warkentin, T. E.: How I diagnose and manage HIT. Hematology, 2011, 2011, 143–149.

  • Bakchoul, T., Greinacher, A.: Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. Ther. Adv. Hematol., 2012, 3(4), 237–251.

  • Furlan, M., Robles, R., Solenthaler, M., et al.: Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood, 1997, 89(9), 3097–3103.

  • Zheng, X. L., Wu, H. M, Shang, D., et al.: Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica, 2010, 95(9), 1555–1562.

  • Levy, G. G., Nichols, W. C., Lian, E. C., et al.: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 2001, 413(6855), 488–494.

  • George, J. N., Al-Nouri, Z. L.: Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am. Soc. Hematol. Educ. Program, 2012, 2012(1), 604–609.

  • George, J. N.: How I treat patients with thrombotic thrombocytopenic purpura – 2010. Blood, 2010, 116(20), 4060–4069.

  • Scully, M.: Rituximab in the treatment of TTP. Hematology, 2012, 17(Suppl. 1), S22–S24.

  • Swisher, K. K., Terrell, D. R., Vesely, S. K., et al.: Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion, 2009, 49(5), 873–887.

  • Vesely, S. K., Li, X., McMinn, J. R., et al.: Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2004, 44(8), 1149–1158.

  • Burwick, R. M., Feinberg, B. B.: Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta, 2013, 34(2), 201–203.

  • Mezödy, M., Diószeghy, C., Pénzes, I.: HELLP syndrome, an unusual form of pregnancy toxicosis. [HELLP szindróma: a terhességi toxicosis ritka formája.] Orv. Hetil., 1995, 136(50), 2733–2736. [Hungarian]

  • Warren, B. L., Eid, A., Singer, P., et al.: High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA, 2001, 286(15), 1869–1878.

  • Wada, H., Matsumoto, T., Hatada, T.: Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev. Hematol., 2012, 5(6), 643–652.

  • Levi, M., Toh, C. H., Thachil, J., et al.: Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br. J. Haematol., 2009, 145(1), 24–33.

  • Curtis, B. R., Swyers, J., Divgi, A., et al.: Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood, 2002, 99(6), 2054–2059.

  • Arnold, D. M., Nazi, I., Warkentin, T. E., et al.: Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus. Med. Rev., 2013, 27(3), 137–145.

  • Curtis, B. R., McFarland, J. G.: Detection and identification of platelet antibodies and antigens in the clinical laboratory. Immunohematology, 2009, 25(3), 125–135.

  • Lifeline: Endre Kelemen. Lancet, 1999, 354(9185), 1220.

  • Young, N. S., Scheinberg, P., Calado, R. T.: Aplastic anemia. Curr. Opin. Hematol., 2008, 15(3), 162–168.

  • Scheinberg, P.: Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am. Soc. Hematol. Educ. Program, 2012, 2012(1), 292–300.

  • Bowie, E. J., Owen, C. A. Jr.: Standardization of the bleeding time. Scand. J. Haematol., 1980, 37(Suppl.), 87–94.